Inicio
Este sitio está destinado a profesionales de la salud.

Paradigmas en evolución en el cáncer de pulmón: Módulo 1 – Limitaciones de los tratamientos actuales

Compartir

Descripción

Esta actividad cuenta con el apoyo de una subvención independiente para educación médica de la Alianza BioNTech-BMS. Este programa de formación en línea ha sido diseñado para profesionales sanitarios de todo el mundo.

Este módulo de microaprendizaje dirigido por expertos explora el cambiante panorama terapéutico del cáncer de pulmón avanzado, analizando las limitaciones de los estándares actuales de tratamiento y el papel emergente de las terapias biespecíficas PD-(L)1 × VEGF. A través de una revisión de la evidencia clínica más reciente y de su fundamento biológico, los expertos ofrecen perspectivas prácticas sobre cómo estos nuevos agentes pueden transformar las futuras estrategias terapéuticas y mejorar los resultados en los pacientes.

¿Prefiere leer en su lugar? Consulte nuestro Resumen Clínico Clave aquí.

Aspectos destacados de la sesión

  • Explore las limitaciones de las estrategias terapéuticas actuales para el CPCNP avanzado y la necesidad no cubierta de enfoques terapéuticos más duraderos.
  • Comprenda el fundamento científico del doble bloqueo de PD-(L)1 × VEGF, incluido su potencial para superar la inmunosupresión y la angiogénesis tumoral.
  • Revise la evidencia clínica más reciente que respalda las terapias biespecíficas emergentes PD-(L)1 × VEGF y su posible papel en la evolución del tratamiento.
  • Aplique la evidencia emergente a la práctica clínica identificando cómo las nuevas terapias biespecíficas pueden influir en las futuras decisiones terapéuticas y mejorar los resultados de los pacientes.

Público objetivo

Esta actividad está dirigida a oncólogos médicos, neumólogos, enfermeros especializados (nurse practitioners), asistentes médicos (physician associates), farmacéuticos, personal de enfermería y otros profesionales sanitarios implicados en la atención de pacientes con cáncer de pulmón, incluido el cáncer de pulmón no microcítico (CPNPC) y el cáncer de pulmón microcítico (CPM).

Profesorado

Edward Garon, MD, es Director del Programa de Oncología Torácica del Jonsson Comprehensive Cancer Center de la UCLA y Profesor Asociado de la UCLA. Reconocido especialista en oncología torácica, sus intereses clínicos y de investigación se centran en el cáncer de pulmón, el desarrollo de biomarcadores y la innovación en ensayos clínicos. El Dr. Garon ha dirigido numerosos ensayos clínicos nacionales e internacionales de fases I–III, incluidos estudios que contribuyeron a la aprobación de múltiples terapias oncológicas y de un diagnóstico complementario.

Declaraciones de intereses

De acuerdo con las directrices de EBAC®, todos los ponentes y moderadores que participan en este programa han declarado cualquier posible conflicto de interés que pudiera influir en sus presentaciones. El Comité Organizador/Director del Curso es responsable de garantizar que todos los posibles conflictos de interés relevantes para el evento se comuniquen a los participantes antes del inicio de las actividades de formación continuada.

El Dr. Edward Garon, miembro del profesorado de esta actividad, ha declarado las siguientes relaciones financieras mantenidas durante los últimos 36 meses con las siguientes empresas no elegibles:

Consultor y/o asesor de: AbbVie, AstraZeneca, Arrivent, Bayer, Bicycle, Black Diamond Therapeutics, BridgeBio, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GSK, Gilead, Hexagon, I-Mab, IO Biotech, iTeos, Merck, Nuvalent, Oxford Bio, Pfizer, Regeneron, Samsung, Sanofi, Servier, Strata, Synthekine, Transcode y Verastem.

Subvenciones/Apoyo a la investigación (institucional) de: ABL-Bio, Arrivent, AstraZeneca, Bayer, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Iovance Biotherapeutics, Merck, Novartis, Prelude, Regeneron, Synthekine y TILT Biotherapeutics.

Propiedad intelectual: Motif Neoepitopes for Cancer Immunotherapy.

El personal de MedAll, así como los planificadores y revisores, no tienen relaciones financieras relevantes con empresas no elegibles que deban declarar.

Información sobre la acreditación EBAC® CME

Esta actividad ha sido planificada e implementada de acuerdo con los requisitos y políticas de acreditación del European Board for Accreditation of Continuing Education for Health Professionals (EBAC).

MedAll es un proveedor acreditado por EBAC desde 2025. El European Board for Accreditation of Continuing Education for Health Professionals (EBAC) acredita programas de formación médica continuada (CE) dirigidos a la comunidad médica internacional.

Este programa está acreditado por el European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) por 15 minutos de formación efectiva.

En cumplimiento de las directrices de EBAC, todos los ponentes y presidentes de sesión que participan en este programa han declarado o indicado cualquier posible conflicto de interés que pudiera introducir sesgos en sus presentaciones. El Comité Organizador/Director del Curso es responsable de garantizar que todos los posibles conflictos de interés relevantes para el evento sean comunicados a los participantes antes del inicio de las actividades de formación continuada.

EBAC® mantiene acuerdos de reconocimiento mutuo de equivalencia sustancial con el Accreditation Council for Continuing Medical Education (ACCME) de los Estados Unidos y con el Royal College of Physicians and Surgeons of Canada.

Gracias a un acuerdo entre el European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) y la American Medical Association (AMA), los médicos pueden convertir los créditos EBAC® de CME externos en AMA PRA Category 1 Credits™. La información sobre el proceso de conversión de créditos EBAC® a créditos AMA está disponible en el sitio web de la AMA. Otros profesionales sanitarios pueden obtener de la AMA un certificado de participación en una actividad susceptible de conversión a AMA PRA Category 1 Credit™.

El Accreditation Council for Continuing Medical Education (ACCME) y el Royal College of Physicians and Surgeons of Canada mantienen un acuerdo de equivalencia sustancial de sus sistemas de acreditación con EBAC.

EBAC® es miembro de la International Academy for CPD Accreditation (IACPDA) y miembro asociado de la International Association of Medical Regulatory Authorities (IAMRA).

Cómo obtener su crédito EBAC® CME

Para obtener su crédito CME y descargar su certificado, participe en la actividad y complete la evaluación al finalizar. Una vez completada la evaluación, recibirá un enlace para acceder a su certificado.

Coste de participación

La participación en este programa es gratuita.

Esta actividad de formación continuada estará disponible desde el 22 de julio de 2026 hasta el 14 de julio de 2027.

Tiempo estimado para completar esta actividad: 15 minutos.

Comunidades similares

Ver todo

Eventos y vídeos bajo demanda similares

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

I'm Edward Garin, and I will be, uh, in this segment addressing the limitations of current, uh, standard of care. And we will be focusing on non-small cell lung cancer. Before we begin, these are our disclosures. Please find here the detailed accreditation information. And finally, please take note of this information. We will start with a polling question. Um, in this polling question, we have a 64 year old patient, uh, who has metastatic non-squamous, non-small cell lung cancer. The patient is, uh, discussing treatment options and to explain why the oncology field is moving towards therapies that simultaneously target The immune system and tumor angiogenesis. Uh, you as the practitioner, uh, referenced foundational trial data that combined, uh, PDL-1 inhibitor, uh, uh, an antibody along with an antibody directed against, uh, VEGF alongside standard chemotherapy. Um, based on the clinical data evaluating a PDL-1 inhibitor plus a VEGF inhibitor and chemotherapy, Um, in this case, it was, uh, otezallizumab, bevacizumab, carboplatin, and paclitaxel versus, uh, just a VEGF, uh, inhibitor and chemotherapy, uh, in this case, bevacizumab and carboplatin and paclitaxel. Uh, what was the hazard ratio for progression-free survival in the intention to treat population? Uh, the choices here are A, uh, has a ratio of less than 0.4, B, uh, has a ratio of, uh, 0.6 to 6.9. Uh, C, a hazard ratio of 0.7 to 0.8, or D, a hazard ratio of 0.8 or more. OK. We'll now go on to sort of the historic benchmarks. And um really, there's been a tremendous amount of progress over the last several years in the management of non-small cell lung cancer. And, um, we'll be speaking more about uh precision oncology later in, uh, in this presentation. Uh, but, uh, at least in the, the early 2000s, uh, really the only tools we had available to us were chemotherapy approaches. And what you can see here is that Uh, when multiple different chemotherapy approaches were evaluated, one versus the other, there really was very little difference. Um, there were some toxicity differences, but in terms of effectiveness, uh, what we saw was really the same. There also, uh, and, and this is still actually a standard today, docetaxel was approved. Um, uh, uh, about 25 years ago, um, based on, uh, approval, uh, for improvements over, uh, best supportive care. And you can see the overall metrics here, um, which in many respects are somewhat disappointing. Pointing. At the time, the response rate was, uh, was about 7%, uh, with a median, uh, overall survival of 7 months. Uh, docetaxel does remain a standard of care. Um, interestingly, probably based on some improvements in things like supportive medications, um, we do have somewhat better outcomes with, uh, docetaxel. But, um, still, uh, our options in previously treated patients is limited. I would argue that for uh patients without driver mutations, uh, really the major advance in uh recent years has been, uh, the availability of immunotherapy. And, um, immunotherapy, it was originally approved in previously treated patients. Uh, but that data really has now become largely irrelevant, as most people, certainly in the United States would receive a PD1 or PDL1 inhibitor, um, in the frontline setting. Now, there are multiple different, uh, agents that are approved. So I will not be going through the data on each, uh, but we'll be tending to go through sort of the first data set approved. Um, in an individual setting. And for, uh, patients in a frontline setting, the original approval was for monotherapy with pembrolizumab in patients with uh PDL1 expression in at least half of their tumor cells. Um, and you can see here with progression-free survival on the left, um, showing, uh, really tremendous benefits for this population of pembrolizumab over chemotherapy. And on the right, you can see the overall survival benefit, uh, again, showing very impressive hazard ratios. Uh, this, you know, certainly is exciting data. And over time, we have, uh, seen that, that these benefits, uh, are in many cases, uh, maintained. There is at this point, similar data in this upfront setting for patients who receive, uh, emiblimab, uh, an alternate PD1 inhibitor, or the PDL1 inhibitor, otezlalizumab. One of the things that I think is particularly exciting, uh, about this class of agents is that there appear to be some patients that have true durable responses. And you can see, um, here is published data, um, from a five-year follow-up. There's now over 10-year follow-up on these patients from the original pembrolizumab study. You can see, uh, on the left here, um, is overall survival in treatment naive patients, um, which is really, I think today, the more relevant population than on the right, the, the previously treated patients. And you can see that, um, that really a, a good percentage of the patients, um, are alive 5 years after the initiation of therapy. Um, you can see that for the entire population, it's over 15% and nearly 30% for the population who had PDL1 in at least 50% of their tumor cells. As you are aware, there is now also data for chemotherapy. Um, and what you see here is data from the keynote 189 study showing progression-free survival above and overall survival when pembrolizumab is added to, uh, to chemotherapy. Um, the red is placebo, showing the chemotherapy alone. Um, there now is similar data along with chemotherapy for, uh, for cemiblimab, uh, as well. And as you can see here, um, even in these aggressive therapies, um, you can see those who have, uh, less than 1% PDL1 expression. Appear to have at least some numeric benefit, but it is not as great as, uh, as the other patients. And what you can also see is that the great majority of these patients have progressed, um, really even at, at a year. Um, and, and I think that, that, that is quite telling when one looks at the, uh, the overall survival on the right. Um, you can see still, um, benefits across the board. But outside of these patients with high PDL one expression, which are at the bottom, um, you know, most of these patients, uh, see a marginal benefit, um, really underscoring the importance, um, really in all patients of having additional options, um, that would, would improve. Obviously, there is a group who does very well, but we don't know upfront who those people always are. Um, here, you can see similar data. I won't go through the breakdown based on PDL one expression, but similar data on the left progression-free survival, the right and the overall survival, um, for squamous cell carcinoma, the prior data that I showed was for non-squamous disease. And again, you can see the addition of pembrolizumab, um, it does show an improvement, uh, over chemotherapy alone. Um, there are some other approaches that people have looked at. And one, Um, has been adding antiangiogenic therapy. Um, this is, uh, a data set that as we have started to see data coming back from by specific Uh, drugs that are targeting both, uh, PD1 or PDL1 along with, uh, VEGF or VEGF receptor. You can see that, uh, this has become, uh, sort of something that people have looked at more in this study. Um, otezallizumab, uh, along with bevacizumab, carboplatin, and paclitaxel was compared to the same regimen without, uh, otezlalizumab. Otezlalizumab, of course, is a PDL-1 inhibitor. And what you can see here is that uh the, there was a, a, a hazard ratio between 0.6 and 0.65 for um the addition of otezallizumab to bevacizumab, carboplatin, and, uh, paclitaxel. Uh, I'm not going to go too in-depth into um CTA4 inhibition. Uh, this is a somewhat controversial, uh, topic in, in the management of non-small cell lung cancer. Um, this is from the Checkmate 227 study. This is the schema for this study. And, um, as part of this study, patients were randomized based on PDL1 expression greater than or less than 1%, uh, to different arms, one of which in each arm, can included, uh, a combination of devolumab along with ipilimumab. Um, this study did show, uh, good outcomes in those patients. Although it is hard to know how it would compare to, for instance, uh,